Editor: Atta-ur-Rahman

Frontiers in Clinical Drug Research - Anti-Cancer Agents

Volume 7

eBook: US $79 Special Offer (PDF + Printed Copy): US $134
Printed Copy: US $95
Library License: US $316
ISSN: 2451-8905 (Print)
ISSN: 2215-0803 (Online)
ISBN: 978-1-68108-776-4 (Print)
ISBN: 978-1-68108-775-7 (Online)
Year of Publication: 2021
DOI: 10.2174/97816810877571210701

Introduction

Frontiers in Clinical Drug Research - Anti-Cancer Agents is a book series intended for pharmaceutical scientists, postgraduate students and researchers seeking updated and critical information for developing clinical trials and devising research plans in anti-cancer research. Reviews in each volume are written by experts in medical oncology and clinical trials research and compile the latest information available on special topics of interest to oncology and pharmaceutical chemistry researchers. The seventh volume of the book features reviews on these topics:

· Essential oils and monoterpenes as potential anti-cancer agents

· Drug delivery systems and emerging immunotherapeutic strategies for the treatment of glioblastoma

· CTDNA in solid tumors

· Cholesterol treatments (including Pitavastatin) and their potential in cancer treatment

Preface

Frontiers in Clinical Drug Research - Anti-Cancer Agents presents recent developments of various therapeutic approaches against different types of cancer. The book is a valuable resource for pharmaceutical scientists, postgraduate students, and researchers seeking updated and critical information for developing clinical trials and devising research plans in anti-cancer research.

The five chapters in this volume are written by eminent authorities in the field. Chapter 1 presents the latest research progress in the use of essential oils and monoterpenes as anti-cancer agents. Chapter 2 gives an overview of current innovative approaches to glioblastoma, focusing on the therapeutic benefits of immunotherapeutic agents and drug delivery systems. Chapter 3 summarizes the roles of ctDNA in clinical practice for diagnosis, treatment choices and responses to therapy in various solid cancers. Chapter 4 focuses on the anti-cancer effects of pitavastatin, including its mechanism of action as well as the potential adverse reactions linked to its clinical use. Chapter 5 discusses the biphasic role of cholesterol, in and around the cancer tumor, as a model target for anti-cancer therapeutic management.

I hope that the readers will find these reviews valuable and thought-provoking so that they may trigger further research in the quest for new and novel therapies against cancers.

I am grateful for the timely efforts made by the editorial personnel, especially Mr. Mahmood Alam (Director Publications) and Mrs. Salma Sarfaraz (Senior Manager Publications) at Bentham Science Publishers.


Atta-ur-Rahman, FRS
Kings College
University of Cambridge
Cambridge
UK

RELATED BOOKS

.Modern Cancer Therapies and Traditional Medicine: An Integrative Approach to Combat Cancers.
.Frontiers in Anti-Cancer Drug Discovery.
.Current and Future Application of Artificial Intelligence in Clinical Medicine.
.Thrombosis in Cancer: .